Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. CureVac N.V.
  6. Company
    CVAC   NL0015436031

CUREVAC N.V.

(CVAC)
  Report
Delayed Quote. Delayed Nasdaq - 01/21 04:00:00 pm
18.73 USD   -14.28%
01/21Health Care Stocks Retreat This Afternoon
MT
01/21Health Care Stocks Drifting Lower in Friday Trade
MT
01/21CureVac Shares Drop After BofA Securities Downgrade
MT
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Business Summary
Logo CureVac N.V.
CureVac AG is a Germany-based biotechnology company. The Company is engaged in the therapeutic development of messenger Ribonucleic Acid (mRNA) and RNA-based vaccines. CureVac AG focuses on developing vaccines for infectious diseases and drugs to treat cancer and rare diseases. The Company's pipeline focuses on three areas: cancer immunotherapy, prophylactic vaccines, and protein-based therapies.

Number of employees : 554 people.
Sales per Business
20192020Delta
Tumour Immunotherapy19.49100%55.71100% +185.81%
USD in Million
Sales per region
2020
United States39.7371.3%
Belgium10.0418%
Netherlands3.005.4%
Germany2.153.9%
Switzerland0.791.4%
USD in Million
Managers
Name Title Age Since
Franz-Werner Haas Chief Executive Officer 51 2020
Pierre Kemula Chief Financial Officer & Managing Director 47 2021
Mariola Fotin-Mleczek Chief Technology Officer 47 2018
Igor Splawski Chief Scientific Officer 53 2020
Malte Greune Chief Operating & Production Officer - 2021
Sarah Fakih, Dr. Vice President-Investor Relations - -
Antony Blanc, Dr. Managing Director 54 2021
Ulrike Gnad-Vogt, Dr. Chief Development Officer - 2021
Klaus Edvardsen, Dr. Chief Development Officer - 2021
Patrick Baumhof Senior Vice President-Technology - -
Members of the board
Name Title Age Since
Baron Jean StÚphenne Chairman-Supervisory Board 71 2015
Ralf Clemens, Dr. Member-Supervisory Board 68 2015
Mathias Hothum, Dr. Member-Supervisory Board 55 2015
Hans Christoph Tanner, Dr. Member-Supervisory Board 70 2015
Craig A. Tooman Member-Supervisory Board 55 2019
Friedrich von Bohlen und Halbach, Dr. Vice Chairman-Supervisory Board 58 2015
Viola Bronsema, Dr. Member-Supervisory Board 58 2020
Equities
Vote QuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 186,599,758 83,865,132 44.9% 0 0.0% 44.9%
Shareholders
NameEquities%
dievini Hopp BioTech holding GmbH & Co. KG 78,362,024 41.9%
Government of Germany 29,871,441 16.0%
GlaxoSmithKline plc 14,935,721 7.99%
Dietmar Hopp 7,743,750 4.14%
Baillie Gifford & Co. 3,923,340 2.10%
Bill & Melinda Gates Foundation Trust (Investment Management) 3,134,780 1.68%
Florian von der Muelbe 1,164,400 0.62%
SSgA Funds Management, Inc. 530,784 0.28%
T. Rowe Price Associates, Inc. (Investment Management) 483,371 0.26%
Union Investment Privatfonds GmbH 460,820 0.25%
Brand Portfolio
In partnership withAllbrands.markets
More brands of CureVac N.V.